Neutropenia in patients under treatment with clozapine and COVID-19 infection
Introduction Clozapine is among the most effective antipsychotics used for treatment resistant schizophrenia. Adverse reactions to clozapine include neutropenia. Case series report that clozapine-treated patients with COVID-19 have no documented neutropenia. Objectives We sought to investigate t...
| Published in: | European Psychiatry |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2021-04-01
|
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S092493382101796X/type/journal_article |
| _version_ | 1850093093942984704 |
|---|---|
| author | S. Bonaccorso A. Ricciardi S. Ouabbou C. Theleritis A. Ross-Michaelides A. Metastasio N. Stewart M. Mohammed F. Schifano |
| author_facet | S. Bonaccorso A. Ricciardi S. Ouabbou C. Theleritis A. Ross-Michaelides A. Metastasio N. Stewart M. Mohammed F. Schifano |
| author_sort | S. Bonaccorso |
| collection | DOAJ |
| container_title | European Psychiatry |
| description |
Introduction
Clozapine is among the most effective antipsychotics used for treatment resistant schizophrenia. Adverse reactions to clozapine include neutropenia. Case series report that clozapine-treated patients with COVID-19 have no documented neutropenia.
Objectives
We sought to investigate the potential adverse effect of coronavirus disease (COVID-19) in patients taking clozapine.
Methods
We retrospectively inspected data of 13 consecutive patients on clozapine, admitted to Highgate Mental Health Centre -Camden & Islington NHS Foundation Trust between March and June 2020. Selection was based on their COVID-19 symptoms presentation and/or COVID-19 positive test. We used a linear regression model with COVID status as independent variable and absolute neutrophil count (ANC) as dependent variable to inform about a correlation between COVID-19 status and neutrophil count. STATA was used for statistics.
Results
We collected data on thirteen patients of which nine were male. The median age was of 41.97 years; six subjects were Black, three were Asian and four were White Caucasian. Ten subjects tested positive to COVID-19 and 3 were suspected cases -these latter were excluded from stastical analysis. During COVID-19 infection, neutrophils count (ANC) dropped significantly to 4.215 from a baseline value of 5.337. The beta values of 0.83 shows that ANC declined significantly during COVID-19 infection (p =<.0001, R2 = 95%). In three of thirteen patients, ANC drop was significant and changed the patients’ monitoring status from green to amber and required frequent blood tests.
Conclusions
Clinicians should bear in mind that a significant drop in neutrophils count may occur in COVID-19 -infected patients taking clozapine.
Disclosure
No significant relationships.
|
| format | Article |
| id | doaj-art-e43aeb93b4d349569318047a2a31e894 |
| institution | Directory of Open Access Journals |
| issn | 0924-9338 1778-3585 |
| language | English |
| publishDate | 2021-04-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| spelling | doaj-art-e43aeb93b4d349569318047a2a31e8942025-08-20T00:08:07ZengCambridge University PressEuropean Psychiatry0924-93381778-35852021-04-0164S677S67710.1192/j.eurpsy.2021.1796Neutropenia in patients under treatment with clozapine and COVID-19 infectionS. Bonaccorso0A. Ricciardi1S. Ouabbou2C. Theleritis3A. Ross-Michaelides4A. Metastasio5N. Stewart6M. Mohammed7F. Schifano8Highgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United Kingdom1st Psychiatry Dept, National and Kapodistrian University of Athens, Athens, GreeceHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomHighgate Mental Health Centre, Camden & Islington NHS Foundation Trust, London, United KingdomPsychiatry And Psychopharmacology, University of Hertfordshire, Hertfordshire, United Kingdom Introduction Clozapine is among the most effective antipsychotics used for treatment resistant schizophrenia. Adverse reactions to clozapine include neutropenia. Case series report that clozapine-treated patients with COVID-19 have no documented neutropenia. Objectives We sought to investigate the potential adverse effect of coronavirus disease (COVID-19) in patients taking clozapine. Methods We retrospectively inspected data of 13 consecutive patients on clozapine, admitted to Highgate Mental Health Centre -Camden & Islington NHS Foundation Trust between March and June 2020. Selection was based on their COVID-19 symptoms presentation and/or COVID-19 positive test. We used a linear regression model with COVID status as independent variable and absolute neutrophil count (ANC) as dependent variable to inform about a correlation between COVID-19 status and neutrophil count. STATA was used for statistics. Results We collected data on thirteen patients of which nine were male. The median age was of 41.97 years; six subjects were Black, three were Asian and four were White Caucasian. Ten subjects tested positive to COVID-19 and 3 were suspected cases -these latter were excluded from stastical analysis. During COVID-19 infection, neutrophils count (ANC) dropped significantly to 4.215 from a baseline value of 5.337. The beta values of 0.83 shows that ANC declined significantly during COVID-19 infection (p =<.0001, R2 = 95%). In three of thirteen patients, ANC drop was significant and changed the patients’ monitoring status from green to amber and required frequent blood tests. Conclusions Clinicians should bear in mind that a significant drop in neutrophils count may occur in COVID-19 -infected patients taking clozapine. Disclosure No significant relationships. https://www.cambridge.org/core/product/identifier/S092493382101796X/type/journal_articleclozapineCOVID-19neutropeniaschizophrénia |
| spellingShingle | S. Bonaccorso A. Ricciardi S. Ouabbou C. Theleritis A. Ross-Michaelides A. Metastasio N. Stewart M. Mohammed F. Schifano Neutropenia in patients under treatment with clozapine and COVID-19 infection clozapine COVID-19 neutropenia schizophrénia |
| title | Neutropenia in patients under treatment with clozapine and COVID-19 infection |
| title_full | Neutropenia in patients under treatment with clozapine and COVID-19 infection |
| title_fullStr | Neutropenia in patients under treatment with clozapine and COVID-19 infection |
| title_full_unstemmed | Neutropenia in patients under treatment with clozapine and COVID-19 infection |
| title_short | Neutropenia in patients under treatment with clozapine and COVID-19 infection |
| title_sort | neutropenia in patients under treatment with clozapine and covid 19 infection |
| topic | clozapine COVID-19 neutropenia schizophrénia |
| url | https://www.cambridge.org/core/product/identifier/S092493382101796X/type/journal_article |
| work_keys_str_mv | AT sbonaccorso neutropeniainpatientsundertreatmentwithclozapineandcovid19infection AT aricciardi neutropeniainpatientsundertreatmentwithclozapineandcovid19infection AT souabbou neutropeniainpatientsundertreatmentwithclozapineandcovid19infection AT ctheleritis neutropeniainpatientsundertreatmentwithclozapineandcovid19infection AT arossmichaelides neutropeniainpatientsundertreatmentwithclozapineandcovid19infection AT ametastasio neutropeniainpatientsundertreatmentwithclozapineandcovid19infection AT nstewart neutropeniainpatientsundertreatmentwithclozapineandcovid19infection AT mmohammed neutropeniainpatientsundertreatmentwithclozapineandcovid19infection AT fschifano neutropeniainpatientsundertreatmentwithclozapineandcovid19infection |
